SKYE BIOSCIENCE
Skye Bioscience is a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids, designed to alleviate a variety of diseases and symptoms by selectively targeting CB1 and CB2 receptors. Skye Bioscience is developing a novel and proprietary class of product candidates that are designed to target the body's nervous and immune systems without inducing many of the undesirable side effects typically associated with currently available therapeutics.
SKYE BIOSCIENCE
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2011-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.skyebioscience.com
Total Employee:
1+
Status:
Active
Contact:
(949) 396-0330
Email Addresses:
[email protected]
Total Funding:
43.84 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Microsoft Exchange Online Amazon Office 365 Mail GoDaddy DNS Google Google Cloud COVID-19
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Aptose Biosciences
Aptose Biosciences is a biopharmaceutical company focused on the discovery, research and development of novel, first-in-class
Oyster Point Pharmaceuticals
Oyster is a clinical stage pharmaceutical company focused on the discovery development & commercialization .
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Samorn Biosciences
Samorn Biosciences is a pharmaceuticals industry that focuses on the development, medical affairs and commercial services.
Stealth BioTherapeutics
Stealth BioTherapeutics is a clinical-stage biotechnology company focused on genetic diseases.
Current Employees Featured
Founder
Stock Details
Investors List
SCHNEIDER Brothers
SCHNEIDER Brothers investment in Post-IPO Equity - Skye Bioscience
Midtown Partners
Midtown Partners investment in Post-IPO Equity - Skye Bioscience
TYLT Ventures
TYLT Ventures investment in Post-IPO Equity - Skye Bioscience
TYLT Ventures
TYLT Ventures investment in Post-IPO Equity - Skye Bioscience
Key Employee Changes
| Date | New article |
|---|---|
| 2022-03-03 | Skye Bioscience Retains Novotech as CRO for Phase 1 Trial of Glaucoma Drug Candidate |
| 2021-10-05 | Skye Bioscience Appoints Kaitlyn Arsenault as Chief Financial Officer |
Official Site Inspections
http://www.skyebioscience.com
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Skye Bioscience"
Skye Bioscience — Developing Next-generation Obesity Drugs
We are a biopharmaceutical company developing next-generation molecules to treat obesity and metabolic diseases. Our focus is on advancing first-in-class drugs with the potential to provide …See details»
Company Information - Skye Bioscience, Inc.
Skye Bioscience (Nasdaq: SKYE) is a biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled …See details»
Investor Relations :: Skye Bioscience, Inc. (SKYE)
Nov 21, 2024 · Skye Bioscience (Nasdaq: SKYE) is a biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G …See details»
Skye Bioscience, Inc. (SKYE) Company Profile & Facts - Yahoo …
Skye Bioscience, Inc., a biopharmaceutical company, focuses on unlocking new therapeutic pathways for metabolic health through the development of molecules that modulate G-protein …See details»
Skye Bioscience Closes Acquisition of Emerald Health …
Nov 11, 2022 · San Diego, California-- (Newsfile Corp. - November 10, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid …See details»
Skye Bioscience Inc. | LinkedIn
Skye Bioscience (Nasdaq: SKYE) is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled...See details»
Skye Bioscience - Overview, News & Similar companies - ZoomInfo
May 10, 2024 · Skye Bioscience contact info: Phone number: (858) 410-0266 Website: www.skyebioscience.com What does Skye Bioscience do? Skye Bioscience is a …See details»
Obesity — Skye Bioscience
Skye is advancing its next-generation peripheral CB1 inhibitor, nimacimab, with the goal of uniquely realizing the potential of this mechanism as an alternative anti-obesity therapeutic with potentially healthier, more sustainable clinical …See details»
Skye Bioscience, Inc. (SKYE) Company Profile & Overview - Stock …
6 days ago · Skye Bioscience, Inc., a biopharmaceutical company, focuses on unlocking new therapeutic pathways for metabolic health through the development of molecules that …See details»
Skye Bioscience Company Profile - Office Locations, Competitors
Mar 19, 2021 · Skye Bioscience has 4 employees across 2 locations. See insights on Skye Bioscience including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
Skye & University of Mississippi: Leveraging more than …
Feb 18, 2021 · At Skye, we believe in the significant possibilities (and recognize the gap in the market) for what bioengineered cannabinoid-based therapies can achieve in generating safer and more effective therapeutic outcomes.See details»
Skye Bioscience Appoints Dr. Karen Smith to Board of Directors
Jul 3, 2024 · Skye plans to start a Phase 2 clinical trial in obesity in Q3 2024 for Nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, comparing monotherapy …See details»
Skye Bioscience Inc, SKYE:NMQ profile - FT.com - Financial Times
Skye Bioscience Inc (SKYE:NMQ) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more.See details»
Skye Bioscience Uplists to The Nasdaq Global Market - Yahoo …
Apr 10, 2024 · Skye is focused on unlocking the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis and …See details»
Skye Bioscience Initiates First-in-Human Phase 1 Clinical Trial for …
Nov 16, 2022 · San Diego, California-- (Newsfile Corp. - November 16, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a …See details»
Skye Bioscience Announces $50.25 Million Private Placement …
Jan 29, 2024 · Financing co-led by a leading life science investor and 5AM Ventures expected to fully fund obesity Phase 2 trial assessing nimacimab, Skye's differentiated peripheral CB1 …See details»
Publications - Skye Bioscience
Skye Bioscience scientists and researchers from collaborating organizations have published scientific articles regarding our proprietary cannabinoid-based therapies in peer-reviewed …See details»
Skye Bioscience Reports Second Quarter 2024 Financial Results …
SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical-stage biopharmaceutical company focused on unlocking …See details»
Skye Completes $17M Financing and Acquires Novel Phase 2 …
Aug 21, 2023 · Skye raised $17M in new capital and acquired Bird Rock Bio Inc. ("Bird Rock"). With Bird Rock's lead asset, nimacimab, Skye intends to advance two complementary but …See details»
News Releases - Skye Bioscience, Inc.
Nov 18, 2024 · Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in …See details»